Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Medical Specialties (29)
- Medical Sciences (20)
- Clinical Epidemiology (10)
- Life Sciences (9)
- Epidemiology (8)
-
- Internal Medicine (8)
- Diseases (6)
- Biological Phenomena, Cell Phenomena, and Immunity (5)
- Influenza Virus Vaccines (5)
- Mental and Social Health (5)
- Community Health and Preventive Medicine (4)
- Immunology and Infectious Disease (4)
- Infectious Disease (4)
- Influenza Humans (4)
- Bioinformatics (3)
- Biomedical Informatics (3)
- Critical Care (3)
- Pathology (3)
- Pediatrics (3)
- Pulmonology (3)
- Respiratory Tract Diseases (3)
- Allergy and Immunology (2)
- Biochemistry, Biophysics, and Structural Biology (2)
- Emergency Medicine (2)
- Health Services Research (2)
- Maternal and Child Health (2)
- Medical Immunology (2)
Articles 31 - 31 of 31
Full-Text Articles in COVID-19
Canakinumab To Reduce Deterioration Of Cardiac And Respiratory Function In Sars-Cov-2 Associated Myocardial Injury With Heightened Inflammation (Canakinumab In Covid-19 Cardiac Injury: The Three C Study), Calvin C Sheng, Debasis Sahoo, Siddharth Dugar, Robier Aguillon Prada, Tom Kai Ming Wang, Ossama K Abou Hassan, Danielle Brennan, Daniel A Culver, Prabalini Rajendram, Abhijit Duggal, A Michael Lincoff, Steven E Nissen, Venu Menon, Paul C Cremer
Canakinumab To Reduce Deterioration Of Cardiac And Respiratory Function In Sars-Cov-2 Associated Myocardial Injury With Heightened Inflammation (Canakinumab In Covid-19 Cardiac Injury: The Three C Study), Calvin C Sheng, Debasis Sahoo, Siddharth Dugar, Robier Aguillon Prada, Tom Kai Ming Wang, Ossama K Abou Hassan, Danielle Brennan, Daniel A Culver, Prabalini Rajendram, Abhijit Duggal, A Michael Lincoff, Steven E Nissen, Venu Menon, Paul C Cremer
Faculty, Staff and Student Publications
BACKGROUND: In patients with Covid-19, myocardial injury and increased inflammation are associated with morbidity and mortality. We designed a proof-of-concept randomized controlled trial to evaluate whether treatment with canakinumab prevents progressive respiratory failure and worsening cardiac dysfunction in patients with SARS-CoV2 infection, myocardial injury, and high levels of inflammation.
HYPOTHESIS: The primary hypothesis is that canakiumab will shorten time to recovery.
METHODS: The three C study (canakinumab in Covid-19 Cardiac Injury, NCT04365153) is a double-blind, randomized controlled trial comparing canakinumab 300 mg IV, 600 mg IV, or placebo in a 1:1:1 ratio in hospitalized Covid-19 patients with elevations in troponin …